Zervanos, D.-I.; Galatou, E.; Miliotou, A.N.; Theodoroula, N.F.; Grigoriadis, N.; Vizirianakis, I.S.
Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical Setting. Future Pharmacol. 2025, 5, 43.
https://doi.org/10.3390/futurepharmacol5030043
AMA Style
Zervanos D-I, Galatou E, Miliotou AN, Theodoroula NF, Grigoriadis N, Vizirianakis IS.
Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical Setting. Future Pharmacology. 2025; 5(3):43.
https://doi.org/10.3390/futurepharmacol5030043
Chicago/Turabian Style
Zervanos, Damianos-Ioannis, Eleftheria Galatou, Androulla N. Miliotou, Nikoleta F. Theodoroula, Nikolaos Grigoriadis, and Ioannis S. Vizirianakis.
2025. "Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical Setting" Future Pharmacology 5, no. 3: 43.
https://doi.org/10.3390/futurepharmacol5030043
APA Style
Zervanos, D.-I., Galatou, E., Miliotou, A. N., Theodoroula, N. F., Grigoriadis, N., & Vizirianakis, I. S.
(2025). Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical Setting. Future Pharmacology, 5(3), 43.
https://doi.org/10.3390/futurepharmacol5030043
